ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OVB Ovoca Bio Plc

0.825
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ovoca Bio Plc LSE:OVB London Ordinary Share IE00B4XVDC01 EUR0.125 (CDI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.825 0.75 0.90 0.825 0.825 0.83 119,941 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.46M -5.61M -0.0688 -0.12 668.82k
Ovoca Bio Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker OVB. The last closing price for Ovoca Bio was 0.83p. Over the last year, Ovoca Bio shares have traded in a share price range of 0.55p to 14.25p.

Ovoca Bio currently has 81,563,806 shares in issue. The market capitalisation of Ovoca Bio is £668,823 . Ovoca Bio has a price to earnings ratio (PE ratio) of -0.12.

Ovoca Bio Share Discussion Threads

Showing 1101 to 1121 of 1425 messages
Chat Pages: Latest  45  44  43  42  41  40  39  38  37  36  35  34  Older
DateSubjectAuthorDiscuss
22/2/2022
16:16
DAVEY the onloy MM on 21p, if they move up we are off a lot higher in my opinion.
mickinvest
22/2/2022
16:16
This looks like going higher -
tomboyb
22/2/2022
16:12
The approved manufacturing site for Orenetide will be operated by two reputable pharmaceutical manufacturers - Nativa and OncoTarget, with commercial production of Orenetide expected to start in Spring 2022. Ovoca Bio is currently in discussions with a number of partners to explore a potential license partnerships for sales of Orenetide on the Russian market.

Spring 2022 folk, it's happening.

mickinvest
22/2/2022
16:09
mm, its on the rise again. decisions, decisions!
abbynat
22/2/2022
16:08
agree to you all. must admit i was busy looking elsewhere so i missed the rns, at 50% i would have sold so maybe i'll hang on again, yet again.seems to be the story with some of mine recently. i'm trying to get rid of some of the small fish that don't want to swim far in my modest portfolio.
gla.

abbynat
22/2/2022
16:06
I don't think many of the pump and dumpers got in on this, be lucky if there are 100k trades under 16p after the news came out.
mickinvest
22/2/2022
16:01
I'm telling you they are really valuing this wrong atm.

Perhaps not the best of days for Russian news but with the cash in the bank, this deal and major trials in Australia this is a 50p stock in the making.

You go and look at what valuations other Bio's have with similar

dave4545
22/2/2022
16:00
There is, however a problem if you say you will do something and do the converse -

That is deceit -

Back to OVB, the news is excellent -

and there is more news in the pipeline -

tomboyb
22/2/2022
15:59
I think intraday Rns's should be abolished

Either 7am or 4.30pm

If they have this news to announce wait until the market closes

Do not let those parasite conmen get in cheaper than us when we have held 30 months ffs.

I do not know why companies do this

dave4545
22/2/2022
15:59
Them numptys play with pocket money they aint moving any share
gooner1886
22/2/2022
15:54
However, OVB this is excellent news -

HIGHLIGHTED BIT -

tomboyb
22/2/2022
15:52
Dave -

In terms of traders, I think you have to trade in and out of this market otherwise you will be left behind -

Took a trade at THG today and almost skimmed 10% -

Look at it now, back down again -

Sentiment is not there yet in these markets -

tomboyb
22/2/2022
15:51
Look at the trades just after, the usual suspect pump and dump merchants who have all sold already

Worth at least double the current price after that news

dave4545
22/2/2022
15:50
Look at the trades before it -

Selling at 10pish -

tomboyb
22/2/2022
15:48
Nice day to announce it :-)
mickinvest
22/2/2022
15:45
Kirill Golovanov, Chief Executive Officer of Ovoca Bio plc, said: "Marketing authorisation approval for Orenetide in Russia is a welcome development for HSDD patients and a major step that provides Ovoca Bio with a solid foundation to engage in distribution agreements for commercialisation of the treatment in Russia. We are currently in several partnership discussions and will provide an update on our progress in due course.



We are also continuing our development programme for Orenetide in a wider international markets which are Ovoca's principal target. Phase II dose-ranging study assessing Orenetide being conducted in Australia and New Zealand has reached over 70% of participants' enrolment, paving the way for Ovoca Bio target to reach 100% ennrolment of participants by mid-2022."

tomboyb
22/2/2022
15:42
shame they let the pump and dump merchants in like toptradersadvfn

he's already dumped

dave4545
22/2/2022
15:39
wow you day traders are so fast
dave4545
22/2/2022
15:36
excellent -
tomboyb
21/2/2022
07:44
I wonder if the rns feed for OVB is broken?
jibba jabber
17/2/2022
07:06
I can't keep up with the newsflow here, said no one.
jibba jabber
Chat Pages: Latest  45  44  43  42  41  40  39  38  37  36  35  34  Older

Your Recent History

Delayed Upgrade Clock